Victory Capital Management
ADMA icon

Victory Capital Management’s ADMA Biologics ADMA Stock Holding History

Victory Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$611K Buy
67,812
+4,447
+7% +$70.2K ﹤0.01% 1984
2025
Q4 		$1.16M Sell
63,365
-176,168
-74% -$2.97M ﹤0.01% 1759
2025
Q3 		$3.51M Buy
239,533
+54,869
+30% +$941K ﹤0.01% 1438
2025
Q2 		$3.36M Sell
184,664
-3,158
-2% -$64.4K ﹤0.01% 1441
2025
Q1 		$3.73M Buy
187,822
+77,874
+71% +$1.35M ﹤0.01% 1370
2024
Q4 		$1.89M Buy
109,948
+38,002
+53% +$715K ﹤0.01% 1513
2024
Q3 		$1.44M Sell
71,946
-12,100
-14% -$188K ﹤0.01% 1612
2024
Q2 		$940K Buy
84,046
+55,322
+193% +$464K ﹤0.01% 1735
2024
Q1 		$190K Sell
28,724
-468
-2% -$2.56K ﹤0.01% 2231
2023
Q4 		$132K Buy
29,192
+5,465
+23% +$20.2K ﹤0.01% 2301
2023
Q3 		$84.9K Buy
23,727
+837
+4% +$3.22K ﹤0.01% 2322
2023
Q2 		$84.5K Sell
22,890
-533
-2% -$1.98K ﹤0.01% 2334
2023
Q1 		$77.5K Buy
+23,423
New +$81K ﹤0.01% 2388

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Victory Capital Management's ADMA Position: Q1 2026 in Review

Victory Capital Management increased its ADMA Biologics (ADMA) stake by 7% in Q1 2026, buying an estimated $70.2K and bringing the position to 67,812 shares worth $611K. The position accounts for ﹤0.01% of the portfolio, ranked #1984.

Victory Capital Management first reported a position in ADMA in Q1 2023 and has held it in 13 quarters since. The position peaked at $3.73M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Victory Capital Management held 67,812 shares of ADMA Biologics worth $611K as of Q1 2026.
  • Victory Capital Management bought 4,447 ADMA Biologics shares in Q1 2026, an estimated $70.2K.
  • ADMA Biologics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1984 holding.
  • Victory Capital Management first reported a position in ADMA Biologics in Q1 2023 and has held it in 13 quarters since.
  • Victory Capital Management's ADMA Biologics position peaked at $3.73M in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.